Home › Immune System and Disorders › New York › New York City
Immune System and Disorders clinical trials in New York City, NY
12 studies for Immune System and Disorders are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
- Memorial Sloan Kettering Cancer Center, New York
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
- Memorial Sloan Kettering Cancer Center, New York
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecruitingPhase 1/2
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Abatacept for the Treatment of Giant Cell Arteritis
RecruitingPhase 3
- Hospital for Special Surgery, New York
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
RecruitingPhase 3
- Icahn School of Medicine at Mount Sinai, New York
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RecruitingPhase 2
- Inmagene Site 21, New York
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RecruitingPhase 2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
RecruitingPhase 2
- Columbia University Irving Medical Center, New York
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
RecruitingPhase 1/2
- Columbia University, New York
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RecruitingPhase 1/2
- Mt Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Biologics And Clinical Immunology Cohort at Sinai
RecruitingObservational study
- Mount Sinai, New York
About Immune System and Disorders
Your immune system is made up of cells, tissues, and organs that fight infections and diseases. Learn how it works, and about diseases of the immune system.
More about Immune System and Disorders on MedlinePlus
Immune System and Disorders trials in other cities
- Washington, DC13 studies
- Philadelphia, PA10 studies
- Boston, MA10 studies
- Atlanta, GA9 studies
- Portland, OR9 studies
- Houston, TX9 studies
- Los Angeles, CA8 studies
- Chicago, IL8 studies
- Cleveland, OH8 studies
- Milwaukee, WI6 studies
- Seattle, WA6 studies
- Cedar Rapids, IA6 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.